Anticoagulation clinics and the monitoring of anticoagulant therapy

Richard Charney, Elaine Leddomado, David N. Rose, Valentin Fuster

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Patients attending an anticoagulation clinic were studied to delineate predisposing risk factors for bleeding and thromboembolic episodes. Seventy-three patients were observed for a total of 921.8 patient-treatment months. The mean duration of treatment was 12.6 months (range 3-36 months). No major bleed occurred (a bleed which caused discontinuation of therapy, hospitalization or death). Thirty-two patients had minor bleeding episodes (0.42 bleeds per patient-year of treatment). The average prothrombin time ratio during the third to the sixth month of therapy was predictive of the bleeding risk. There was no association between bleeding and age, sex, indication for anticoagulation therapy or associated illnesses. Four thromboembolic episodes occurred (0.05 per patient-year of treatment), 3 arterial and 1 venous. At the time of the one venous thromboembolic event the prothrombin time ratio was subtherapeutic. In all 3 patients with arterial thromboembolism the mean 3- to 6-month prothrombin time ratio was less than or equal to the lower limit of the recommended range of 1.6-2.5. In our study prothrombin time ratios of 1.3-1.5 for venous thromboembolic disease and 1.6-2.5 for arterial thromboembolic disease were not associated with thromboembolism or major bleeding. Anticoagulation clinics facilitate the close monitoring of patients on oral anticoagulant therapy.

Original languageEnglish (US)
Pages (from-to)197-206
Number of pages10
JournalInternational Journal of Cardiology
Volume18
Issue number2
DOIs
StatePublished - 1988
Externally publishedYes

Fingerprint

Anticoagulants
Prothrombin Time
Hemorrhage
Thromboembolism
Therapeutics
Physiologic Monitoring
Causality
Hospitalization

Keywords

  • Anticoagulant
  • Hemorrhage
  • Thromboembolism

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Anticoagulation clinics and the monitoring of anticoagulant therapy. / Charney, Richard; Leddomado, Elaine; Rose, David N.; Fuster, Valentin.

In: International Journal of Cardiology, Vol. 18, No. 2, 1988, p. 197-206.

Research output: Contribution to journalArticle

Charney, Richard ; Leddomado, Elaine ; Rose, David N. ; Fuster, Valentin. / Anticoagulation clinics and the monitoring of anticoagulant therapy. In: International Journal of Cardiology. 1988 ; Vol. 18, No. 2. pp. 197-206.
@article{39dc920b20da4414aafdb3187f2faf07,
title = "Anticoagulation clinics and the monitoring of anticoagulant therapy",
abstract = "Patients attending an anticoagulation clinic were studied to delineate predisposing risk factors for bleeding and thromboembolic episodes. Seventy-three patients were observed for a total of 921.8 patient-treatment months. The mean duration of treatment was 12.6 months (range 3-36 months). No major bleed occurred (a bleed which caused discontinuation of therapy, hospitalization or death). Thirty-two patients had minor bleeding episodes (0.42 bleeds per patient-year of treatment). The average prothrombin time ratio during the third to the sixth month of therapy was predictive of the bleeding risk. There was no association between bleeding and age, sex, indication for anticoagulation therapy or associated illnesses. Four thromboembolic episodes occurred (0.05 per patient-year of treatment), 3 arterial and 1 venous. At the time of the one venous thromboembolic event the prothrombin time ratio was subtherapeutic. In all 3 patients with arterial thromboembolism the mean 3- to 6-month prothrombin time ratio was less than or equal to the lower limit of the recommended range of 1.6-2.5. In our study prothrombin time ratios of 1.3-1.5 for venous thromboembolic disease and 1.6-2.5 for arterial thromboembolic disease were not associated with thromboembolism or major bleeding. Anticoagulation clinics facilitate the close monitoring of patients on oral anticoagulant therapy.",
keywords = "Anticoagulant, Hemorrhage, Thromboembolism",
author = "Richard Charney and Elaine Leddomado and Rose, {David N.} and Valentin Fuster",
year = "1988",
doi = "10.1016/0167-5273(88)90165-9",
language = "English (US)",
volume = "18",
pages = "197--206",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Anticoagulation clinics and the monitoring of anticoagulant therapy

AU - Charney, Richard

AU - Leddomado, Elaine

AU - Rose, David N.

AU - Fuster, Valentin

PY - 1988

Y1 - 1988

N2 - Patients attending an anticoagulation clinic were studied to delineate predisposing risk factors for bleeding and thromboembolic episodes. Seventy-three patients were observed for a total of 921.8 patient-treatment months. The mean duration of treatment was 12.6 months (range 3-36 months). No major bleed occurred (a bleed which caused discontinuation of therapy, hospitalization or death). Thirty-two patients had minor bleeding episodes (0.42 bleeds per patient-year of treatment). The average prothrombin time ratio during the third to the sixth month of therapy was predictive of the bleeding risk. There was no association between bleeding and age, sex, indication for anticoagulation therapy or associated illnesses. Four thromboembolic episodes occurred (0.05 per patient-year of treatment), 3 arterial and 1 venous. At the time of the one venous thromboembolic event the prothrombin time ratio was subtherapeutic. In all 3 patients with arterial thromboembolism the mean 3- to 6-month prothrombin time ratio was less than or equal to the lower limit of the recommended range of 1.6-2.5. In our study prothrombin time ratios of 1.3-1.5 for venous thromboembolic disease and 1.6-2.5 for arterial thromboembolic disease were not associated with thromboembolism or major bleeding. Anticoagulation clinics facilitate the close monitoring of patients on oral anticoagulant therapy.

AB - Patients attending an anticoagulation clinic were studied to delineate predisposing risk factors for bleeding and thromboembolic episodes. Seventy-three patients were observed for a total of 921.8 patient-treatment months. The mean duration of treatment was 12.6 months (range 3-36 months). No major bleed occurred (a bleed which caused discontinuation of therapy, hospitalization or death). Thirty-two patients had minor bleeding episodes (0.42 bleeds per patient-year of treatment). The average prothrombin time ratio during the third to the sixth month of therapy was predictive of the bleeding risk. There was no association between bleeding and age, sex, indication for anticoagulation therapy or associated illnesses. Four thromboembolic episodes occurred (0.05 per patient-year of treatment), 3 arterial and 1 venous. At the time of the one venous thromboembolic event the prothrombin time ratio was subtherapeutic. In all 3 patients with arterial thromboembolism the mean 3- to 6-month prothrombin time ratio was less than or equal to the lower limit of the recommended range of 1.6-2.5. In our study prothrombin time ratios of 1.3-1.5 for venous thromboembolic disease and 1.6-2.5 for arterial thromboembolic disease were not associated with thromboembolism or major bleeding. Anticoagulation clinics facilitate the close monitoring of patients on oral anticoagulant therapy.

KW - Anticoagulant

KW - Hemorrhage

KW - Thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=0023954856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023954856&partnerID=8YFLogxK

U2 - 10.1016/0167-5273(88)90165-9

DO - 10.1016/0167-5273(88)90165-9

M3 - Article

VL - 18

SP - 197

EP - 206

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 2

ER -